Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Newer thrombolytic agents.

Annals of the Academy of Medicine, Singapore - 1 May 1999

Verstraete M

Abstract excerpt

Several lines of research towards improvement of thrombolytic agents are being explored, including the construction of mutants of plasminogen activators, chimeric plasminogen activators, conjugates of plasminogen activators with monoclonal antibodies, and plasminogen activators from animal or bacterial origin. Some of these new thrombolytic agents have shown promise in animal models of venous or arterial...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amino Acid Sequence
Share to Fibrinolytic Agents
Share to Molecular Sequence Data

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mutation

Share to Myocardial Infarction

Share to Recombinant Proteins

Share to Tissue Plasminogen Activator

Source

Identifiers

PMID: 10575530

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Newer thrombolytic agents.PMID 10575530Read ↗

Pharmacological and clinical impact of the unique molecular structure of a new plasminogen activator.Semantic proximity Read ↗

Strategies for the improvement of thrombolytic agents.Semantic proximity Read ↗

Recombinant variants of tissue-type plasminogen activator containing amino acid substitutions in the fibronectin finger-like domain and the kringle 1 domain.Semantic proximity Read ↗

Tissue-type plasminogen activator: mutants, variants, and adjunctive treatment.Semantic proximity Read ↗

Properties of a novel plasminogen activator (BM 06.022) produced in Escherichia coli.Semantic proximity Read ↗

Redesigning t-PA for improved thrombolytic therapy.Semantic proximity Read ↗

[New types of plasminogen activators].Semantic proximity Read ↗

[Biochemical, pharmacologic and clinical properties of new thrombolytic agents].Semantic proximity Read ↗

Plasminogen mutants activated by thrombin. Potential thrombus-selective thrombolytic agents.Semantic proximity Read ↗

The potential improvement of thrombolytic therapy by targeting with bispecific monoclonal antibodies: why they are used and how they are made.Semantic proximity Read ↗

Thrombolytic properties in a rabbit jugular vein thrombosis model of a tissue-type plasminogen activator mutant lacking the growth factor--and kringle one-domains.Semantic proximity Read ↗

Mechanistic studies on Zymogen-Activator and Adhesion Proteins (ZAAPs) as thrombolytic drugs and bacterial virulence factorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.